In this episode of the Heartbeat Podcast, we delve into the latest findings from a pooled analysis of pivotal clinical trials—SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM. This study uncovers the impact of semaglutide, a GLP-1 receptor agonist, on patients with heart failure with preserved ejection fraction (HFpEF), particularly those struggling with obesity. Join us as we explore how this treatment reduces heart failure events and discuss its implications for clinical practice. With HFpEF being a challenging condition to treat, this episode highlights hope for patients and clinicians alike.
Stay tuned for an insightful discussion, statistics, and the potential future of HFpEF management!
Listen to the Episode Here:
#HFpEF #HeartFailure #Semaglutide #MedicalResearch #Cardiology #HeartHealth #Obesity #Podcast #MedicalScience #GLP1ReceptorAgonist#SELECTStudy #FLOWTrial #STEP_HFpEF #STEP_HFpEF_DM